Metabolic and therapeutic effects of insulin-like growth factor I

E. R. Froesch; P. D. Zenobi; M. Hussain

doi:10.1159/000184148

Metabolic and therapeutic effects of insulin-like growth factor I

E. R. Froesch, P. D. Zenobi, M. Hussain

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

The administration of rhIGF-I in appropriate doses leads to a decrease of insulin and growth hormone secretion and to an increase of insulin sensitivity. In type 2 diabetic patients, IGF-I improves glyceinic profiles. In normal subjects, IGF-I increases energy expenditure and lipid oxidation and has a protein- sparing effect. Total and VLDL-triglycerides as well as LDL-cholesterol are decreased by IGF-I administration. This metabolic profile of IGF-I allows speculation on its possible usefulness in conditions of relative insulin resistance often associated with increased cardiovascular morbidity and mortality.

Original language	English (US)
Pages (from-to)	66-71
Number of pages	6
Journal	Hormone Research in Paediatrics
Volume	42
Issue number	1-2
DOIs	https://doi.org/10.1159/000184148
State	Published - Jan 1 1994
Externally published	Yes

Keywords

Growth hormone inhibition
Insulin inhibition
Insulin sensitivity
Lipid metabolism
rhIGF-I therapy

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.1159/000184148

Cite this

@article{03ff9f887e90493eacd7df826821bfde,

title = "Metabolic and therapeutic effects of insulin-like growth factor I",

abstract = "The administration of rhIGF-I in appropriate doses leads to a decrease of insulin and growth hormone secretion and to an increase of insulin sensitivity. In type 2 diabetic patients, IGF-I improves glyceinic profiles. In normal subjects, IGF-I increases energy expenditure and lipid oxidation and has a protein- sparing effect. Total and VLDL-triglycerides as well as LDL-cholesterol are decreased by IGF-I administration. This metabolic profile of IGF-I allows speculation on its possible usefulness in conditions of relative insulin resistance often associated with increased cardiovascular morbidity and mortality.",

keywords = "Growth hormone inhibition, Insulin inhibition, Insulin sensitivity, Lipid metabolism, rhIGF-I therapy",

author = "Froesch, {E. R.} and Zenobi, {P. D.} and M. Hussain",

year = "1994",

month = jan,

day = "1",

doi = "10.1159/000184148",

language = "English (US)",

volume = "42",

pages = "66--71",

journal = "Hormone Research in Paediatrics",

issn = "1663-2818",

publisher = "S. Karger AG",

number = "1-2",

}

TY - JOUR

T1 - Metabolic and therapeutic effects of insulin-like growth factor I

AU - Froesch, E. R.

AU - Zenobi, P. D.

AU - Hussain, M.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - The administration of rhIGF-I in appropriate doses leads to a decrease of insulin and growth hormone secretion and to an increase of insulin sensitivity. In type 2 diabetic patients, IGF-I improves glyceinic profiles. In normal subjects, IGF-I increases energy expenditure and lipid oxidation and has a protein- sparing effect. Total and VLDL-triglycerides as well as LDL-cholesterol are decreased by IGF-I administration. This metabolic profile of IGF-I allows speculation on its possible usefulness in conditions of relative insulin resistance often associated with increased cardiovascular morbidity and mortality.

AB - The administration of rhIGF-I in appropriate doses leads to a decrease of insulin and growth hormone secretion and to an increase of insulin sensitivity. In type 2 diabetic patients, IGF-I improves glyceinic profiles. In normal subjects, IGF-I increases energy expenditure and lipid oxidation and has a protein- sparing effect. Total and VLDL-triglycerides as well as LDL-cholesterol are decreased by IGF-I administration. This metabolic profile of IGF-I allows speculation on its possible usefulness in conditions of relative insulin resistance often associated with increased cardiovascular morbidity and mortality.

KW - Growth hormone inhibition

KW - Insulin inhibition

KW - Insulin sensitivity

KW - Lipid metabolism

KW - rhIGF-I therapy

UR - http://www.scopus.com/inward/record.url?scp=0027932692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027932692&partnerID=8YFLogxK

U2 - 10.1159/000184148

DO - 10.1159/000184148

M3 - Article

C2 - 7959637

AN - SCOPUS:0027932692

SN - 1663-2818

VL - 42

SP - 66

EP - 71

JO - Hormone Research in Paediatrics

JF - Hormone Research in Paediatrics

IS - 1-2

ER -

Metabolic and therapeutic effects of insulin-like growth factor I

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this